← Back to screener

Organogenesis Holdings Inc. ORGO

Rank #334 · Nasdaq · $0.1B market cap
Audited by RSM US LLP, no going-concern flag in the latest filing.
Score
68.4
P/E
20.0
P/B
0.37
ROE
1.9%
Op. Margin
2.9%
Debt Ratio
42%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★★★☆
Excellent

P/E 20.0x, P/B 0.37x. Ranks in the top 16% of the universe.

Profitability ★★☆☆☆
Weak

ROE 1.9%. Ranks in the top 66% of the universe.

Safety ★★★★☆
Good

Debt ratio 42%. Ranks in the top 21% of the universe. Under 100% is generally considered a safe level.

Growth ★☆☆☆☆
Weak

Revenue decline of 3.9% year over year. Ranks in the top 74% of the universe.

Valuation is the relative strength · Growth is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2016––$-0.0B$0.0B––
2017–$-0.0B$-0.0B$-0.0B–-6992815
2018$0.1B$-0.0B$-0.0B$0.0B-6.34476
2019$0.2B$-0.0B$-0.0B$-0.0B-2.8-730
2020$0.2B$-0.1B$-0.1B$-0.0B-26.7-1078
2021$0.3B$-0.0B$-0.0B$0.0B-11.4372
2022$0.3B$0.0B$0.0B$0.1B7.9388
2023$0.5B$0.1B$0.1B$0.1B15.5130
2024$0.5B$0.0B$0.0B$0.2B4.975
2025$0.4B$0.0B$0.0B$0.3B2.942

← See the full screener